This profile has not been claimed by the company. See reviews below to learn more or submit your own review. How do I know I can trust these reviews about Matrix Absence Management? How do I know I ...
The FDA has authorized urcosimod 0.05% for single-patient expanded access, or compassionate use, in a patient with neuropathic corneal pain, according to a press release from Okyo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results